Blood pressure and hormonal responses to sublingual nifedipine in acute childhood hypertension. 1986

W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer

Twelve infants and children were treated with sublingual application of the calcium antagonist nifedipine. Blood pressure fell within 1 h following administration of nifedipine to age-related normal values. Whereas plasma renin activity, plasma concentrations of aldosterone and arginine vasopressin did not change within 1 h after drug application, plasma noradrenaline rose (p less than 0.05), probably in response to vasodilatation. Plasma concentration of nifedipine at 30 and 60 min after application correlated positively with the fall in mean arterial pressure. Nifedipine was well tolerated and appeared to be an effective and safe drug in the treatment of acute rises of blood pressure in infants and children.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007223 Infant A child between 1 and 23 months of age. Infants
D009060 Mouth Floor The area of the mouth beneath the TONGUE. Floor of Mouth,Sublingual Region,Floor, Mouth,Floors, Mouth,Mouth Floors,Region, Sublingual,Regions, Sublingual,Sublingual Regions
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
April 1989, Archives of disease in childhood,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
August 1988, Archives of disease in childhood,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
January 1983, Harefuah,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
June 1987, The Journal of the Association of Physicians of India,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
March 1983, Israel journal of medical sciences,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
January 1983, Indian heart journal,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
March 1982, Circulation,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
May 1981, Chest,
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
January 1985, Hypertension (Dallas, Tex. : 1979),
W Rascher, and K E Bonzel, and H Ruder, and D E Müller-Wiefel, and K Schärer
August 1986, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!